BioSpace News Archive

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates

BioCryst Pharmaceuticals, Inc. announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme.

A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection (anastomosis) that is created with the minimally invasive Ellipsys® Vascular Access System.

Amidst the COVID-19 surge and countries going back into lockdown, it is critical that our nation and its citizens have an ongoing supply of authentic personal protective equipment (PPE). Fusion PPE continues to deliver genuine PPE including its CDC and NIOSH-approved N95 to medical professionals, businesses, and NOW a growing general consumer clientele.

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high-quality cannabis, announced its financial results for the second quarter ended August 31, 2020.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the launch of new branding for its upcoming oncology clinical trials combining its lead drug candidate, REQORSA™ (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso® (osimertinib), which received U.S. Food and Drug Administration (FDA)

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced that it has entered into a private placement led by an undisclosed leading U.S. public investment fund specializing in life sciences as well as an existing investor, Structured Alpha LP, providing for the purchase of approximately USD$30 million of its common shares,

The demand within the global OTC topical drugs market is slated to increase in the years to follow.

the synthetic analogues of the natural steroid hormones and their mediators. The anti-inflammatory, anti-proliferative, vaso-constrictive, and immunosuppressive effects have been fervently studied by researchers, expanding the avenue for industry players in the cortisone market.

Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with presentations by key opinion leaders in hematology